Publications by the Consortium

• Choukrani G, Álvarez Freile J, Wan W, Egri G, Ustyanovska Avtenyuk N, Wiersma VR, Bremer E, Dähne L.

  Development of vaterite particles for therapeutic protein drug delivery and pH-sensitive release mimicking the tumor microenvironment.

  Particle. 2021.
• Álvarez Freile J, Choukrani G, Zimmermann K, Bremer E, Dähne L.

  Whispering Gallery Modes-based biosensors for real-time monitoring and binding characterization of antibody-based cancer immunotherapeutics.

  Sensors and Actuators B: Chemical. 2021 Nov 346(1):130512.
• Vlaming M, Bilemjian V, Álvarez Freile J, Lourens HJ, van Rooij N, Huls G, van Meerten T, de Bruyn M, Bremer E.

  CD20 positive CD8 T cells are a unique and transcriptionally-distinct subset of T cells with distinct transmigration properties.

  Sci Rep. 2021 Oct 15;11(1): 20499.
• Kucka K, Lang I, Zhang T, Siegmund D, Medler J, Wajant H.

  Membrane lymphotoxin-beta is a novel tumor necrosis factor (TNF) receptor 2 (TNFR2) agonist. Cell

  Death Dis. 2021 Apr 6;12(4):360.
• Aido A, Zaitseva O, Wajant H, Buzgo M, Simaite A.

  Anti-Fn14 Antibody-Conjugated Nanoparticles Display Membrane TWEAK-Like Agonism.

  Pharmaceutics. 2021 Jul 13;13(7):1072.
• Ustyanovska Avtenyuk N, Choukrani G, Ammatuna E, Niki T, Cendrowicz Król E, Lourens HJ, Huls G, Wiersma VR, Bremer E.

  Galectin-9 Triggers Neutrophil-Mediated Anticancer Immunity.

  Biomedicines. 2022, 10(1), 66;
• Medler J, Kucka K, Melo Galegos V, Zhang T, von Rotenhan S, Ulrich J, Bremer E, Hudecek M, Beilhack A, Wajant H. (2021).

  CD40- and 41BB-specific antibody fusion proteins with PDL1 blockade-restricted agonism.

  Theranostics. 2022; 12(4):1486-1499.
• Cendrowicz E, Jacob L, Greenwald S, Tamir A, Pecker I, Tabakman R, Ghantous L, Tamir L, Kahn R, Avichzer J, Aronin A, Amsili S, Zorde-Khvalevsky E, Gozlan Y, Vlaming M, Huls G, van Meerten T, Elhalel Dranitzki M, Foley-Comer A, Pereg Y, Peled A, Chajut A, Bremer E.

  DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity.

  Journal of Experimental and Clinical Research (in press).
• Freile JA, Choukrani G, Bremer E, Daehne L.

  Facing the Challenges of Pharmaceutical Research Using Whispering Gallery Modes-Based Biosensors.

  American Journal of Biomedical Science & Research. 2020 Mar 8(2).
• Choukrani G, Freile JA, Bremer E, Daehne L.

  Using Nanomedicine to Drive Advances in Cancer Immunotherapy: A Mini Review.

  American Journal of Biomedical Science & Research. 2020 Mar 8(2).
• Avtenyuk Ustyanovska N, Visser N, Bremer E, Wiersma VR.

  The Neutrophil: The Underdog That Packs a Punch in the Fight against Cancer.

  International Journal of Molecular Sciences. 2020, 21(21), 7820.
• Jimena Álvarez Freile J, Yuzhu Qi, Lisa Jacob, Maria Franceskin Lobo, Harm Jan Lourens, Gerwin Huls, Edwin Bremer.

  A luminescence-based method to assess antigen presentation and antigen-specific T cell responses for in vitro screening of immunomodulatory checkpoints and therapeutics.

  Front. Immunol., Volume 14, 25 July 2023.
• Vinicio Melo, Levi Collin Nelemans, Martijn Vlaming, Harm Jan Lourens, Valerie R. Wiersma, Vrouyr Bilemjian, Gerwin Huls, Marco de Bruyn, Edwin Bremer.

  EGFR-selective activation of CD27 co-stimulatory signaling by a bispecific antibody enhances anti-tumor activity of T cells.

  Front. Immunol., Volume 14, 20 July 2023.
• Ghizlane Choukrani, Nienke Visser, Natasha Ustyanovska Avtenyuk, Mirjam Olthuis, Glenn Marsman, Emanuele Ammatuna, Harm Jan Lourens, Toshiro Niki, Gerwin Huls, Edwin Bremer and Valerie R. Wiersma.

  Galectin-9 has non-apoptotic cytotoxic activity towards Acute Myeloid Leukemia independent of cytarabine resistance.

  Cell Death Discovery, 2023 Jul 6;9(1):228.
• Martijn Vlaming, Vrouyr Bilemjian, Jimena Álvarez Freile, Vinicio Melo Galegos, Annechien Plat, Gerwin Huls, Hans W Nijman, Marco de Bruyn, Edwin Bremer.

  Tumor infiltrating CD8/CD103/TIM-3-expressing lymphocytes in epithelial ovarian cancer co-express CXCL13 and associate with improved survival.

  Front Immunol. 2022 Oct 21;13:1031746.
• Vrouyr Bilemjian, Martijn R. Vlaming, Jimena Álvarez Freile, Gerwin Huls, Marco De Bruyn*, Edwin Bremer*.

  The novel immune checkpoint GPR56 is predominantly expressed and selectively upregulated in tumor-infiltrating and tumor-reactive lymphocytes.

  Cancers (Basel). 2022.
• Jimena Álvarez Freile, Natasha Ustyanovska Avtenyuk, Macarena González Corrales, Harm Jan Lourens, Gerwin Huls, Tom van Meerten, Ewa Cendrowicz, and Edwin Bremer.

  CD24 is a potential immunotherapeutic target for Mantle Cell Lymphoma.

  Biomedicines. 2022, 10(5), 1175.
• Vinicio Melo Galegos, Edwin Bremer, John Martin.

  Towards immunotherapy-induced normalization of the tumor microenvironment.

  Frontiers in Cell and Developmental Biology. 2022. Vol 10.
• Medler J, Kucka K, Melo Galegos V, Zhang T, von Rotenhan S, Ulrich J, Bremer E, Hudecek M, Beilhack A, Wajant H. (2021).

  CD40- and 41BB-specific antibody fusion proteins with PDL1 blockade-restricted agonism.

  Theranostics, 2022 Jan 1;12(4):1486-1499.